GT Biopharma (GTBP) Appoints Andrew Ritter to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
GT Biopharma Appoints New Member to its Board of Directors
May 15, 2025 9:00 AM EDTSAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Andrew Ritter to its Board of Directors. Mr. Ritter will be replacing current board member Dr. Rajesh Shrotriya, who is resigning from his position.
We are very pleased to welcome Andrew to the Board of Directors. Andrew is a deeply talented biotech executive with a proven track record of... More
